Short answer
Greenwich LifeSciences, Inc. (GLSI) filed its Q1 2026 10-Q quarterly report on Jun 4, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$6M
- −73.6% YoY
- EPS (diluted)
- −$0.39
- −56.0% YoY
Source: XBRL data from the Greenwich LifeSciences, Inc. (GLSI) Q1 2026 10-Q on SEC EDGAR. USD.
Greenwich LifeSciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; clinical-stage company without commercialization
- Net loss $5.7M vs $2.7M YoY; no margin figures disclosed
- Research and development expenses $5.2M, up 129% from $2.3M
- Cash $10.5M vs $6.2M; operating cash use $4.7M vs $1.8M YoY
- ATM offerings generated $9.0M net proceeds; additional capital required for operations and trials
Risk Factors
- No material changes from Form 10-K risk factors for year ended December 31, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Greenwich LifeSciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.